VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its strategic plan, which highlights the construction of three new cleanrooms and the incorporation of new equipment that will multiply its production capacity substantially. VIVEbiotech will now have 600 square meters of clean rooms with 8 nanobioreactors and two large capacity bioreactors.
Thanks to this growth, in 2021 VIVEbiotech will be able to produce lentiviral vectors for advanced clinical trials in which hundreds of patients participate, as well as to attend the commercial scale production of any gene therapy product that uses lentivirus. The trend of the gene therapy market is growing and with the new infrastructure VIVEbiotech will be able to respond to this reality.
The capital increase has been endorsed by VIVEbiotech´s private partners who continue with their commitment to the company and its future. Easo Ventures and Inveready are the new shareholders, the latter being a venture capital fund with extensive experience in biotechnology.
VIVEbiotech is already producing lentiviral vectors for 16 gene therapy projects, 6 of them with CAR-Ts. Customers are located in European countries, the United States, Israel and Australia.
Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology...Read moreShare
Next January the Participants will be announced and the acceleration program will begin. 20 of...Read moreShare
The Basque Government is engaged in the international project to make this production possible in...Read moreShare
La industria vasca prevé una afección global a corto-largo plazo imposible aún de cuantificar,...Read moreShare
AseBio brings together more than 730 companies that employ almost 100,000 people and invest more...Read moreShare
For SMEs, for diversifying markets, internships abroad, international tenders, non-reimbursable subsidies to consolidate exports, subsidies for deployments or specific training in internationalisation.You’re interested, right?